InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
85.87
(
-0.74%
)
Bitcoin
55,707.36
(
-0.25%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

BTH

Send PM Follow Ignore
Followers 16
Posts 4145
Boards Moderated 1
Alias Born 06/11/2010

BTH

Re: exwannabe post# 3014

Friday, 10/29/2010 9:29:58 AM

Friday, October 29, 2010 9:29:58 AM

Post# of 80490

Very few P3 trials are stopped for either futility or the P value meeting some predefined threahold like .001



Then why did The Harv say (several times I might add), that based on the way the "trial is powered, there is a reasonable chance" it would be stopped at the 2nd Interim which would allow for an NDA filing. Merck clearly thought the same way if you listened to their conference call over the summer. So, despite you having said very few trials are stopped, both Merck and Ariad felt there was a "reasonable chance" it would be stopped. Why?

Just because a trial is stat sig at an interim does not get it stopped



Why were the Phase 3 trials in everolimus and temsirolimus stopped then, at the interim?

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up